RSI Oversold Stocks
VALN is flagged as RSI oversold, meaning recent selling pressure has pushed momentum to extreme levels that may lead to a short-term rebound.
VALNEVA SE - ADR (VALN) Stock Price & Overview
NASDAQ:VALN • US92025Y1038
Current stock price
5.35 USD
-0.03 (-0.56%)
Last:
The current stock price of VALN is 5.35 USD. Today VALN is down by -0.56%. In the past month the price decreased by -12.3%. In the past year, price decreased by -18.57%.
VALN Key Statistics
52-Week Range5.15 - 12.25
Current VALN stock price positioned within its 52-week range.
1-Month Range5.15 - 6.4199
Current VALN stock price positioned within its 1-month range.
- Market Cap
- 464.789M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.61
- Dividend Yield
- N/A
VALN Stock Performance
Today
-0.56%
1 Week
-2.73%
1 Month
-12.30%
3 Months
-41.91%
Longer-term
6 Months -42.29%
1 Year -18.57%
2 Years -41.01%
3 Years -53.07%
5 Years -79.41%
10 Years N/A
VALN Stock Chart
VALN Stock Screens
VALN currently appears in the following ChartMill screener lists.
VALN Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VALN. When comparing the yearly performance of all stocks, VALN is a bad performer in the overall market: 90.42% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
VALN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VALN. Both the profitability and financial health of VALN have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
VALN Earnings
On February 19, 2026 VALN reported an EPS of -0.59 and a revenue of 47.69M. The company missed EPS expectations (-36.73% surprise) and beat revenue expectations (22.64% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 19, 2026
PeriodQ4 / 2025
EPS Reported-€0.59
Revenue Reported47.687M
EPS Surprise -36.73%
Revenue Surprise 22.64%
VALN Forecast & Estimates
12 analysts have analysed VALN and the average price target is 13.72 USD. This implies a price increase of 156.42% is expected in the next year compared to the current price of 5.35.
For the next year, analysts expect an EPS growth of 45.79% and a revenue growth -2.38% for VALN
Analysts
Analysts81.67
Price Target13.72 (156.45%)
EPS Next Y45.79%
Revenue Next Year-2.38%
VALN Financial Highlights
Over the last trailing twelve months VALN reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS decreased by -871.43% compared to the year before.
Income Statements
Revenue(TTM)253.30M
Net Income(TTM)-168.78M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.32% | ||
| ROE | -158.97% | ||
| Debt/Equity | 1.76 |
Chartmill High Growth Momentum
EPS Q2Q%-16%
Sales Q2Q%-9.93%
EPS 1Y (TTM)-871.43%
Revenue 1Y (TTM)2.07%
VALN Ownership
Ownership
Inst Owners23.99%
Shares86.88M
Float76.75M
Ins Owners0.21%
Short Float %0.19%
Short Ratio1.43
VALN Industry Overview
VALN operates in the Biotechnology sub-industry within the Health Care sector. This group contains 52 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
36/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
78/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
21%
Outperformed 21% of sub-industries
3 Month Rank
21%
Outperformed 21% of sub-industries
6 Month Rank
36%
Outperformed 36% of sub-industries
Industry Fundamentals & Breadth
- Members
- 52
- New Highs
- 1.9%
- New Lows
- 11.5%
- Average ROE
- 26.7%
- Average Profit Margin
- 29.7%
- Average Operating Margin
- 25.9%
- Average P/E
- 38.6
- Average Fwd P/E
- 30.5
- Average Debt/Equity
- 0.0
VALN Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VALN
Company Profile
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Company Info
IPO: 2007-06-28
VALNEVA SE - ADR
6, Rue Alain Bombard
Saint-Herblain PAYS DE LA LOIRE FR
CEO: Thomas Lingelbach
Employees: 695
Phone: 33228073710
VALNEVA SE - ADR / VALN FAQ
What does VALN do?
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
What is the current price of VALN stock?
The current stock price of VALN is 5.35 USD. The price decreased by -0.56% in the last trading session.
What is the dividend status of VALNEVA SE - ADR?
VALN does not pay a dividend.
What is the ChartMill technical and fundamental rating of VALN stock?
VALN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for VALNEVA SE - ADR?
VALNEVA SE - ADR (VALN) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for VALNEVA SE - ADR?
The Revenue of VALNEVA SE - ADR (VALN) is expected to decline by -2.38% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.